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BACKGROUND/OBJECTIVE: In-home automated external defibrilla-
tors (AEDs) are increasingly recommended as a means for improving
survival of cardiac arrests that occur at home. The current study was
conducted to explore the relationship between individuals’ risk of car-
diac arrest and cost-effectiveness of in-home AED deployment.
DESIGN: Markov decision model employing a societal perspective.
PATIENTS: Four hypothetical cohorts of American adults 60 years of
age at progressively greater risk for sudden cardiac death (SCD): 1) all
adults (annual probability of SCD 0.4%); 2) adults with multiple SCD
risk factors (probability 2%); 3) adults with previous myocardial inf-
arction (probability 4%); and 4) adults with ischemic cardiomyopathy
unable to receive an implantable defibrillator (probability 6%).
INTERVENTION: Strategy 1: individuals suffering an in-home cardiac
arrest were treated with emergency medical services equipped with
AEDs (EMS-D). Strategy 2: individuals suffering an in-home cardiac
arrest received initial treatment with an in-home AED, followed by
EMS.
RESULTS: Assuming cardiac arrest survival rates of 15% with EMS-D
and 30% with AEDs, the cost per quality-adjusted life-year gained
(QALY) of providing in-home AEDs to all adults 60 years of age is
$216,000. Costs of providing in-home AEDs to adults with multiple
risk factors (2% probability of SCD), previous myocardial infarction (4%
probability), and ischemic cardiomyopathy (6% probability) are
$132,000, $104,000, and $88,000, respectively.
CONCLUSIONS: The cost-effectiveness of in-home AEDs is intimately
linked to individuals’ risk of SCD. However, providing in-home AEDs to
all adults over age 60 appears relatively expensive.
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A pproximately 250,000 Americans suffer out-of-hospitalcardiac arrests each year.1,2 Available evidence supports
the use of implantable cardioverter defibrillators (ICDs) in in-
dividuals at highest risk for cardiac arrest (e.g., those with an
ejection fraction of 30%) because their risk of cardiac arrest
is 5% to 10% per year.3–6 However, approximately 70% of out-
of-hospital cardiac arrests occur among individuals at in-
creased risk for sudden cardiac death (SCD) but who lack suf-
ficient risk to warrant a prophylactic ICD.1,7–10
In the absence of an ICD, survival of out-of-hospital
cardiac arrest depends upon a rapid response by emergency
medical services (EMS) to deliver defibrillation. While cardiac
arrest survival rates of 25% have been reported, prolonged
EMS response times and survival rates of 3% to 5% are
common.11–14 In an effort to reduce the time-to-defibrillation
interval and improve cardiac arrest survival, the public health
system has increasingly turned to a strategy of public
access defibrillation (PAD) to augment EMS.15 The strategy
of PAD is predicated upon the idea that automated external
defibrillators (AEDs) should be placed in densely populated
public locations where cardiac arrests are likely to occur.16
A recently published study demonstrated that PAD can
increase cardiac arrest survival,17 but PAD is hampered
by at least 2 important constraints18,19. First, there are an in-
finite number of public locations where cardiac arrests may
occur and AEDs can be deployed; second, PAD is ineffective
for the 50% to 70% of out-of-hospital cardiac arrests that
occur in private homes.7,15,20–22 One potential solution to
the problem of in-home cardiac arrests is to provide individu-
als at increased risk of SCD with personal AEDs for in-home
use. While the idea of home defibrillators has been contem-
plated for many years, only recently have improvements
in technology made in-home AEDs a viable option.15,23,24
The Federal Drug Administration (FDA) responded to these
improvements by approving AEDs for in-home use with a
prescription in 2002 and is currently considering over-the-
counter availability.25,26
However, the relationship between an individual’s risk of
SCD and the cost-effectiveness of in-home AED deployment
relative to EMS is unknown. Accordingly, we developed a de-
cision analytic model to evaluate the clinical and economic
consequences of in-home AED deployment for individuals at
increased risk of SCD in an effort to clarify the relationship
between an individual’s risk of SCD and the cost-effectiveness
of an in-home AED.
METHODS
Literature Review
MEDLINE was used to search the 1966–2003 medical litera-
ture using the terms heart arrest, emergency medical services,
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and public access defibrillation, as were abstracts of
major scientific meetings from 2000 to 2003. Bibliographies
of selected review articles were scanned to identify additional
articles.
Relevant articles were abstracted by one of the authors
(P.C.) to obtain the values for the model. In cases where mul-
tiple publications estimating a particular input were available,
we assessed the methodology of each study and used the es-
timate from the study deemed to be the most methodologically
sound. If no single study was superior, we took the mean of the
estimates provided by the available studies and used broad
confidence intervals to incorporate the range of available esti-
mates into sensitivity analysis.
Decision Analytic Model
We constructed a Markov decision model using the
societal perspective to evaluate the lifetime clinical and
economic impact of 2 alternative strategies in a cohort of
adults 60 years of age (Fig. 1): strategy 1: individuals
suffering an in-home cardiac arrest initially received cardio-
pulmonary resuscitation (CPR) followed by care administered
by EMS equipped with AEDs (EMS-D); strategy 2: individuals
suffering an in-home cardiac arrest were initially treated
with a home AED followed by care administered by
EMS-D (AED). The two strategies differed only in the initial
availability of an AED and its impact on cardiac arrest survival
and costs. All probabilities for model inputs are shown in Table
1. DATA 4.0 (TreeAge Software Inc., Williamstown, MA) and
Excel 2000 (Microsoft Inc., Redmond, WA) were used for all
analyses.
Patient Population, Probability of Cardiac Arrest,
and AED Use
While the risk of SCD among an unselected population of
American adults is 0.4% per year, the probability of cardiac
arrest among adults with multiple SCD risk factors ranges
from 2% to 6% per year depending upon the precise popula-
tion.1,3,5,8,9,27–37 We evaluated the cost-effectiveness of in-
home AEDs among 4 cohorts of adults at progressively in-
creasing risk of SCD: 1) all adults (initial probability of SCD at
age 60 of 0.4%); 2) adults with multiple SCD risk factors such
as hypertension or left ventricular hypertrophy (initial proba-
bility 2%); 3) adults with previous myocardial infarction (initial
probability 4%); and 4) adults with ischemic cardiomyopathy
and an ejection fraction 30%, but unable/unwilling to re-
ceive an ICD (initial probability 6%).
Individuals in each cohort were considered to be at risk for
both SCD and death from other causes on an annual basis. The
initial risk of both SCD and overall mortality in each cohort were
derived from the medical literature and assumed to increase in
subsequent years based upon life-table estimates.27,38
Available evidence suggests that 50% to 70% of all out-of-
hospital arrests occur at home and that at least 50% are wit-
nessed.15,20–22,39 However, even if a cardiac arrest occurs at
home, is witnessed, and an AED is available, it is likely that the
device will not always be used. In the base-case, it was as-
sumed that 50% of all arrests occurred at home and that 40%
of these arrests were witnessed and treated with the available
in-home AED. These assumptions were evaluated in sensitivity
analyses. It was assumed that an in-home AED was used ex-
clusively for arrests that occurred in the home of the individual
for whom the device was prescribed and that the only person at
FIGURE 1. Decision analytic model for strategy 2.
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risk of suffering an in-home cardiac arrest was the individual
for whom the AED was prescribed. It was also assumed that all
individuals purchasing an in-home AED lived with at least one
other person capable of using the device.
Costs
Costs included in the model are shown in Table 1. Individuals
in each of the 4 cohorts accrued annual medical costs based
upon values in the published literature.40–44 The cost of an in-
home AED was $2,000;45 AED maintenance costs were also
included in the model.45,46 We assumed that for each AED
purchased, two individuals would undergo CPR and AED
training on a biennial basis (the individual ‘‘at-risk’’ and one
cohabitant). Additional costs were included to account for the
time required for training.47
Previous studies have demonstrated that the cost of hos-
pitalization for cardiac arrest victims varies, depending upon
whether an individual dies in the hospital or survives to dis-
charge.46,48–51 Hospitalization costs among cardiac arrest sur-
vivors accounted for the expectation that most would receive
an ICD. Future medical costs incurred by cardiac arrest sur-
vivors were included in the model and accounted for the like-
lihood that a proportion of survivors would require long-term
care.46,48,49 Historical costs were adjusted to 2004 dollars us-
ing an inflation rate of 2.5% to reflect inflation in the consumer
price index between 1999 and 2002.52 Future costs and ben-
efits were discounted at 3% in accordance with accepted
guidelines.53
Effectiveness of Strategy 1
In the absence of an in-home AED, individuals suffering an
arrest at home would be treated by EMS equipped with AEDs
(EMS-D). While survival rates of 25% have been reported with
optimized EMS-D, survival rates of 3% to 5% are common in
congested urban and remote rural areas.11–14,54–56; this vari-
ation in survival reflects the fact that cardiac arrest survival
falls by approximately 10% per-minute delay in defibrilla-
tion.57 In the base-case, 15% of in-home cardiac arrest vic-
tims were assumed to survive to hospital discharge based
upon survival rates with an optimized EMS-D system and a
time-to-defibrillation interval of 10minutes.58,59 This assump-
tion was deliberately optimistic for EMS-D and it is likely that
many cardiac arrest victims experience a time-to-defibrillation
interval of 15minutes or more, thus resulting in cardiac arrest
survival rates of 10% or less. Sensitivity analysis was used to
assess the impact of varying time-to-defibrillation intervals
and corresponding changes in arrest survival rates on overall
cost-effectiveness.
Effectiveness of Strategy 2
The benefit of in-home AEDs is directly related to any increase
in survival that they confer (strategy 2) relative to EMS-D-
based care (strategy 1). No published studies have examined
the impact of in-home AEDs on cardiac arrest survival. How-
ever, studies examining the impact of AED deployment in
public locations (PAD) on cardiac arrest survival are highly
Table 1. Model Inputs
Variable Base-case Range Reference
Probabilities
Probability arrest will occur at home .50 .40–.70 (15, 20–22)
Probability AED will be used on in-home arrest victim .40 .25–.75 (20)
Probability of initial resuscitation with emergency medical services (EMS) .30 .15–.60 (11–13)
Probability of initial resuscitation with AED .50 .40–.80 (18, 19, 75, 76)
Probability of surviving to hospital discharge with EMS .15 .03–.30 (11–14, 55, 56)
Probability of surviving to hospital discharge with AED .30 .20–.50 (18, 19, 75, 76)
Annual probability of dying—cardiac arrest survivors .15 .10–.30 (3, 60–62)
Probability of surviving cardiac arrest unimpaired .75 .50–.85 (60, 63, 64)
Probability of surviving arrest moderately impaired .15 .05–.30 (60, 63, 64)
Probability of surviving arrest severely impaired .10 .00–.20 (60, 63, 64)
Costs, $
Annual medical costs
Unselected population 4,000 3,000–8,000 (40, 41)
Multiple risk factors 5,000 4,000–12,000 (42)
Previous myocardial infarction 5,500 4,500–14,000 (43)
Congestive heart failure 10,000 8,000–20,000 (44)
AED purchase 2,000 250–2,500 (45)
AED maintenance 40 20–80 (45)
Annual cost of AED training 50 25–100 Personal written
communication, Johnson
County Red Cross
Time for training at $17/hour for 4 hours 70 35–140 (47)
AED supplies per use 150 100–200 (45)
Postarrest hospitalization
Survive to discharge 54,000 40,000–100,000 (48–50)
Death in hospital 15,000 3,000–30,000 (46, 50, 51)
Annual medical costs for arrest survivors 13,000 9,000–20,000 (46, 48, 49)
Other parameters
Quality of life
Unimpaired .85 .7–1 (65, 67)
Moderately impaired .20 0–.40 (68)
Severely impaired .1 0–.2 (68)
EMS, emergency medical services; AED, automated external defibrillator.
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applicable.17–19 Based upon these studies and an average
time-to-defibrillation interval of 5minutes, cardiac arrest sur-
vival with an in-home AED was estimated to be 30% in the
base-case.57–59
Life Gained Among Arrest Survivors
Cardiac arrest survivors have an annual mortality of approx-
imately 15% per year.3,60–62 Survivors of cardiac arrest were
assigned to 1 of 3 cerebral performance categories (CPC) based
upon published data: CPC-1, unimpaired with no residual def-
icit; CPC-2, moderately impaired with minimal deficits, but
able to live independently; or CPC-3/4, severely impaired, re-
quiring institutional care.60,63–66 Utility scores for unimpaired
survivors were based upon studies by Nichol et al.67 and Gran-
ja et al.65 Utility scores for the moderately and severely im-
paired survivors were estimated based upon published data
from stroke survivors with similar levels of functional impair-
ment.68
Sensitivity Analysis
Because of uncertainty regarding the precise values of many of
the model inputs, a series of 3 sensitivity analyses were per-
formed. First, one-way sensitivity analyses were performed
across the range of values available for each of the model in-
puts. Next, two-way sensitivity analyses were conducted using
combinations of model variables to further assess the impact
of uncertainty on our findings. Finally, Monte Carlo simulation
was conducted to allow all variables to vary simultaneously in
further effort to assess the robustness of our findings. For this
analysis, variables related to costs and survival were assigned
log-normal distributions, while all others were given normal
distributions.53,69
RESULTS
Cost-effectiveness of In-home AED
The cost-effectiveness of the 4 alternative strategies for in-
home AED deployment is shown in Table 2. Providing in-home
Table 2. Risk Factors for Sudden Cardiac Death











All adults age 60 .004 .01 5175 .024 216,000 (1, 27)
Multiple SCD risk factors .02 .04 4930 .037 132,000 (28–31)
Previous MI .04 .06 4925 .047 104,000 (8, 32–34)
Ischemic cardiomyopathy .06 .10 4720 .054 88,000 (3, 5, 35–37)
In-home AED compared to EMS-D.
QALY, quality-adjusted life-year; SCD, sudden cardiac death; MI, myocardial infarction; AED, automated external defibrillator; EMS-D, emergency
medical services equipped with AEDs.
FIGURE 2. Two-way sensitivity analysis involving probability of SCD and life expectancy for arrest survivors.
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AEDs to all adults 60 years of age (0.4% probability of SCD)
costs an incremental $5,175 per person and results in a gain of
0.024 quality-adjusted life-year (QALYs), leading to a cost per
QALY gained of $216,000. Limiting distribution of in-home
AEDs to specific populations at increased risk of SCD results
in improved cost-effectiveness ratios: individuals with multiple
SCD risk factors (2% probability of SCD) cost $132,000 per
QALY; individuals who had suffered a previous myocardial
infarction (4% probability of SCD) cost $104,000 per QALY;
and individuals with ischemic cardiomyopathy who were un-
able/unwilling to receive an ICD (6% probability of SCD) cost
$88,000 per QALY.
One-way Sensitivity Analyses
Results of one-way sensitivity analyses for selected variables
performed on 2 of the selected patient cohorts (multiple SCD
risk factors and ischemic cardiomyopathy) are shown in Table
3. The results were sensitive to the probability that the arrest
occurred at home, the probability that the available AED was
used, and the probability of suffering SCD, as demonstrated
above. The cost-effectiveness of in-home AED deployment was
also sensitive to changes in the relative benefit of AED deploy-
ment (strategy 2) compared to EMS-D care (strategy 1). For
example, for individuals with multiple SCD risk factors, as the
probability of survival to hospital discharge with EMS-D de-
creased from 29% to 3% (corresponding to a time-to-defibril-
lation delay increasing from 5minutes to 20minutes), the
cost-effectiveness ratio for in-home AEDs decreased from
$5,140,000 to $86,000 per QALY gained when compared with
EMS-D. Likewise for individuals with multiple SCD risk fac-
tors, as the probability of arrest survival with an in-home AED
increased from 20% to 50% (corresponding to a time-to-defi-
brillation delay decreasing from 7minutes to 3minutes), the
cost per QALY gained decreased from $328,000 to $76,000.
The cost-effectiveness of in-home AED deployment was rela-
tively insensitive to variations in all cost parameters.
Two-way Sensitivity Analyses
Figure 2 illustrates a two-way sensitivity analysis involving the
probability of an individual suffering SCD and the life expect-
ancy of cardiac arrest survivors. Depending upon the popula-
tion considered, the annual probability of SCD in a cohort 60
years of age may range from 0.4% (all adults) to 6% (adults
with ischemic cardiomyopathy). In addition, while the base-
case assumed that cardiac arrest survivors would live an ad-
ditional 6 years, available evidence suggests that life expect-
ancy may be as little as 3 years or as great as 9 years.
Assuming life expectancy for cardiac arrest survivors of 9
and 6 years, the cost-effectiveness ratio crosses the
$100,000/QALY threshold at annual probabilities of cardiac
arrest of 2% and 4%, but never falls beneath the $50,000/
QALY threshold.
Figure 3 illustrates the impact of a two-way sensitivity
analysis involving the probability of an individual suffering
SCD and the absolute reduction in the time-to-defibrillation
interval afforded by an in-home AED compared to EMS-D care.
In the base-case, it was assumed that cardiac arrest survival
with EMS-D was 15% versus 30% with an in-home AED; this
corresponds to a time-to-defibrillation interval of 10minutes
for EMS-D and 5minutes for an in-home AED (a 5-minute
‘‘time-savings’’ with an in-home AED). If, however, the reduc-
tion in the time-to-defibrillation interval with an in-home AED
is greater, the cost-effectiveness ratio becomes more favorable.
For example, if the time savings with an in-home AED is
15minutes (i.e., time-to-defibrillation interval of 20minutes
and survival of 3% with EMS-D vs time-to-defibrillation inter-
val of 5minutes and survival of 30% with AED) rather than
5minutes, the cost per QALY gained for providing in-home
AEDs to individuals with a 2% probability of SCD falls from
$132,000 to $86,000.
Multiway Sensitivity Analysis
Monte Carlo simulation conducted while holding the annual
risk of cardiac arrest constant at 2% demonstrated a mean
Table 3. Results of One-way Sensitivity Analyses for Selected Variables
Input Range Cost per QALY Gained ($)
Multiple SCD risk factors
(2% risk of SCD)
Ischemic cardiomyopathy
(6% risk of SCD)
Probabilities
Probability arrest will occur at home .4–.7 157,000–103,000 103,000–72,000
Probability AED is used .25–.75 193,000–84,000 123,000–62,000
Probability of resuscitation with EMS .15–.59 100,000–2,900,000 71,000–1,600,000
Probability of resuscitation with AED .40–.80 197,000–78,000 125,000–58,000
Probability of surviving to hospital discharge with EMS .03–.29 86,000–5,100,000 62,000–2,960,000
Probability of surviving to hospital discharge with AED .20–.50 328,000–76,000 198,000–57,000
Probability of surviving arrest unimpaired .50–.85 173,000–120,000 116,000–81,000
Life expectancy of cardiac arrest survivor 3–8 225,000–100,000 69,000–146,000
Costs
AED cost 250–2,500 84,000–145,000 55,000–98,000
AED maintenance 20–80 126,000–144,000 86,000–93,000
AED training course 25–100 124,000–147,000 85,000–95,000
AED training time 35–140 121,000–153,000 84,000–97,000
Hospitalization costs: in-hospital death 3,000–30,000 135,000–128000 91,000–84,000
Hospitalization costs: survive to discharge 40,000–100,000 128,000–144,000 85,000–100,000
Future medical costs (per annum) 9,000–20,000 125,000–142,000 82,000–99,000
QALY, quality-adjusted life-year; SCD, sudden cardiac death; AED, automated external defibrillator; EMS, emergency medical services.
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cost of $176,000 per QALY gained (standard deviation $5,800;
median $159,000). The simulation demonstrated that the cost
per QALY gained fell below $100,000 in 23% of all trials and
below $50,000 in 4%. Monte Carlo simulation conducted while
holding the annual risk of cardiac arrest constant at 4% re-
vealed mean and median costs per QALY gained of $131,000
and $105,000, respectively; increasing the probability of car-
diac arrest to 6% resulted in mean and median of $105,000
and $88,000.
Alternatively, changing 3 of our base-case assumptions
simultaneously: 1) increasing the probability that an in-home
AED will be used from 40% to 60%; 2) decreasing the proba-
bility of cardiac arrest survival with EMS from 15% to 10%;
and 3) increasing the probability of cardiac arrest survival with
an in-home AED from 30% to 40% while holding the annual
probability of cardiac arrest constant at 2% reduced the cost
per QALY gained from $132,000 to $65,000. Maintaining
these 3 changes and simultaneously increasing the annual
probability of cardiac arrest to 4% and 6% resulted in costs per
QALY gained of $56,000 and $50,000, respectively.
DISCUSSION
The current analysis suggests that the cost-effectiveness of in-
home AED is intimately linked to an individual’s risk of cardiac
arrest. While purchase of in-home AEDsmay be reasonable for
adults with increased risk of SCD, providing in-home AEDs to
all adults is expensive when compared to commonly accepted
cost-effectiveness thresholds70,71; our findings also demon-
strate that the cost-effectiveness of in-home defibrillators is
particularly sensitive to the reduction in the time-to-defibril-
lation interval that an in-home AED provides relative to EMS-
D-based care. Although the decision to recommend an in-
home AED to an individual patient is complex, the results of
our cost-effectiveness analysis suggest that several specific
clinical factors (e.g., patient risk, distance/time from EMS
care) should be considered prior to making such a decision.
The fact that the cost-effectiveness of an in-home AED is
sensitive to the probability of an individual suffering a cardiac
arrest demonstrates that risk assessment is critical. While ac-
curately predicting an individual’s risk for SCD is currently
difficult, it is possible to risk stratify individuals using widely
available information such as age, cardiac risk factors, and
history of coronary artery disease. The importance of an indi-
vidual’s risk also reinforces the importance of continued re-
search to allow for more accurate individualized risk
assessment.8,72 Also, our findings demonstrate the impor-
tance of considering the expected time-to-defibrillation inter-
val at an individual’s home. Individuals living in congested
urban or remote rural areas are likely to experience prolonged
delays to defibrillation and thus low survival rates in the ab-
sence of an in-home AED. Conversely, individuals living in
close proximity to trained first responders are likely to experi-
ence shorter delays and receive less benefit from an in-home
AED.
In discussing the current analysis, it is important to note
the limitations of our work. We were deliberately conservative
in all of our model estimates to avoid overestimating the effec-
FIGURE 3. Two-way sensitivity analysis involving probability of SCD and the reduction in the time-to-defibrillation interval offered by in-home
AEDs.
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tiveness of in-home AEDs, but consequently may have under-
estimated the benefits offered by in-home AEDs. For example,
our estimation of 15% survival of cardiac arrest with EMS-D
was based upon an optimized program, but reported survival
rates in most communities are 5% to 10%. We also assumed
that an in-home AED would only benefit the individual for
whom the device had been purchased. However, data are al-
ready emerging to suggest that in-home AEDs are likely to
benefit individuals other than the person for whom the device
was purchased.73,74 Modifying the model in the aforemen-
tioned ways would enhance the cost-effectiveness of in-home
AEDs. In addition, the current analysis did not incorporate the
fact that in-home AEDs could increase anxiety for both pa-
tients and family members, thereby worsening the cost-effec-
tiveness of the intervention. However, such anxiety has not
been previously demonstrated. Finally, our analysis did not
capture potential complications resulting from in-home AED
deployment, but this appears to be justified based upon the
safety record of modern AEDs; the ongoing Home Use AED
(HAT) trial will help to clarify the frequency of such complica-
tions.
In conclusion, in-home AEDs may be a reasonable invest-
ment for individuals at increased risk of SCD, but population-
based deployment to all adults 60 years of age is relatively
expensive. However, modest modifications of our conservative
base-case assumptions make population-based in-home defi-
brillators appear more cost-effective when compared to other
home safety devices that are commonly purchased. FDA ap-
proval of over-the-counter AEDs will force patients and pro-
viders to explicitly assess the risk and value that in-home
AEDs provide.
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